YMAB - Y-mAbs reaches agreement with EMA on the pediatric investigation plan for naxitamab
- Y-mAbs Therapeutics ( NASDAQ: YMAB ) said the European Medicines Agency had agreed to its proposed pediatric investigation plan for naxitamab to treat patients with relapsed/refractory high-risk neuroblastoma.
- A Pediatric Investigation Plan outlines a pharma company’s strategy for investigation of the new medicinal product in the pediatric population and is a required submission as part of the regulatory process for the registration of new medicines in Europe.
For further details see:
Y-mAbs reaches agreement with EMA on the pediatric investigation plan for naxitamab